Journal article
Executive Summary of the Vulvodynia Therapeutic Research Summit
Obstetrics and gynecology (New York. 1953), v 147(2), pp 266-276
Feb 2026
PMID: 41197126
Featured in Collection : Drexel's Newest Publications
Abstract
Therapeutics identified through expert consensus for further research to treat neuroinflammation of provoked vestibulodynia were ketotifen, resiniferatoxin, specialized pro-resolving mediators, luteolin, alpha-lipoic acid, and photoablation.
The current treatment of provoked vestibulodynia involving neuroproliferation is often complete vestibulectomy; however, less invasive treatments are biologically plausible, yet lack study. The International Society for the Study of Women's Sexual Health, the National Vulvodynia Association, the Gynecologic Cancers Research Foundation, and Tight Lipped, a grassroots nonprofit organization that supports people with chronic vulvovaginal and pelvic pain, collectively sponsored a conference, the Vulvodynia Therapeutic Research Summit, held in April 2024. The primary objective of the Vulvodynia Therapeutic Research Summit was to identify options for further research of the treatment of provoked vestibulodynia through expert consensus. After the conference, attendees scored the presented therapeutics in rank order, leading to a hierarchy of merit. Fifteen therapeutic options were presented and ranked in order of most promising to least promising for further study on treating the neuroinflammation of provoked vestibulodynia. The top identified therapeutics for further research were: 1) ketotifen fumarate (mast cell stabilizer with potential to prevent mast cell activation), 2) resiniferatoxin (transient receptor vanilloid 1 agonist causing chemo-inactivation of nerve terminals), 3) specialized pro-resolving mediators or strategies to boost their levels (eg, maresin 1 and 1-trifluoromethoxy-phenyl-3-[1-propionylpiperidin-4-yl] urea), 4) luteolin (flavonoid with potent anti-inflammatory, antioxidant, and neuroprotective properties), 5) alpha-lipoic acid (antioxidant with nerve-specific anti-inflammatory and mast cell stabilizing qualities), and 6) NGFR121W-SNAP IR700 trimer exposed to near-infared light (photoablation targeting nociceptors and sparing surrounding tissue). This executive summary describes the rationale for identifying specific pharmacologic agents and medical devices as targets for research directed toward treatment of the neuroinflammatory process found in the vestibular mucosa of provoked vestibulodynia.
Metrics
10 Record Views
Details
- Title
- Executive Summary of the Vulvodynia Therapeutic Research Summit
- Creators
- Jill M. Krapf - University of British ColumbiaPaul J. YongMarlene D. BerkeNina Bohm-StarkeJacob BornsteinEmanuelle ChrysillaTania T. DempseyMegan L. FalsettaDavid FosterSue W. Goldstein - College Station Medical CenterMichael J. IadarolaSusan Kellogg-Spadt - Drexel University, Obstetrics and GynecologyAndrew J. MannesJohn VogelAndrew T. Goldstein - George Washington University
- Publication Details
- Obstetrics and gynecology (New York. 1953), v 147(2), pp 266-276
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 11
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Obstetrics and Gynecology
- Scopus ID
- 2-s2.0-105027660645
- Other Identifier
- 991022130777704721